Immunoglobulin m efficacy against Cryptococcus neoformans:: Mechanism, dose dependence, and prozone-like effects in passive protection experiments

被引:88
作者
Taborda, CP
Casadevall, A
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, Bronx, NY 10461 USA
关键词
D O I
10.4049/jimmunol.166.3.2100
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The IgM mAbs 12A1 and 13F1 are protective and nonprotective, respectively, against lethal Cryptococcus neoformans infection in mice. To better understand the variables that contribute to IgM efficacy against C, neoformans, we studied the effects: of inoculum size, route of infection, and Ab dose for each of these mAbs, mAb 13F1 did not prolong survival under any condition studied. mAb 12A1 prolonged survival after the administration of certain Ab doses after i.p. infection with defined inocula and promoted phagocytosis, agglutination, and the formation of inflammatory cell rings around yeast cells in vivo. Large Ab doses of mAb 12A1 resulted in either no protection or enhanced infection, consistent with a prozone-like effect. Investigation of this phenomenon revealed that the fungal cell was protected against microbicidal nitrogen-derived oxidants when large amounts of Ab were bound to the C, neoformans capsule. mAb 12A1 was opsonic in vitro for peritoneal, but not splenic or alveolar macrophages, In summary, our results indicate that IgM efficacy against C, neoformans is a function of the route of infection, inoculum, and Ab dose and is associated with its ability to promote opsonization, agglutination, and phagocytic ring formation in vivo. The occurrence of the prozone-like phenomenon implies that high Ab titers are not necessarily beneficial in assuring protection against certain pathogens and that caution should be exercised in using high Ab titer as a measure for vaccine efficacy.
引用
收藏
页码:2100 / 2107
页数:8
相关论文
共 58 条
[1]   INHIBITION OF CRYPTOCOCCUS-NEOFORMANS REPLICATION BY NITROGEN-OXIDES SUPPORTS THE ROLE OF THESE MOLECULES AS EFFECTORS OF MACROPHAGE-MEDIATED CYTOSTASIS [J].
ALSPAUGH, JA ;
GRANGER, DL .
INFECTION AND IMMUNITY, 1991, 59 (07) :2291-2296
[2]   What makes Cryptococcus neoformans a pathogen? [J].
Buchanan, KL ;
Murphy, JW .
EMERGING INFECTIOUS DISEASES, 1998, 4 (01) :71-83
[3]   Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies [J].
Casadevall, A ;
Cleare, W ;
Feldmesser, M ;
Glatman-Freedman, A ;
Goldman, DL ;
Kozel, TR ;
Lendvai, N ;
Mukherjee, J ;
Pirofski, LA ;
Rivera, J ;
Rosas, AL ;
Scharff, MD ;
Valadon, P ;
Westin, K ;
Zhong, ZJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1437-1446
[4]   ANTIBODY IMMUNITY AND INVASIVE FUNGAL-INFECTIONS [J].
CASADEVALL, A .
INFECTION AND IMMUNITY, 1995, 63 (11) :4211-4218
[5]   MONOCLONAL-ANTIBODY BASED ELISAS FOR CRYPTOCOCCAL POLYSACCHARIDE [J].
CASADEVALL, A ;
MUKHERJEE, J ;
SCHARFF, MD .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 154 (01) :27-35
[6]   ANTIBODIES ELICITED BY A CRYPTOCOCCUS-NEOFORMANS TETANUS TOXOID CONJUGATE VACCINE HAVE THE SAME SPECIFICITY AS THOSE ELICITED IN INFECTION [J].
CASADEVALL, A ;
MUKHERJEE, J ;
DEVI, SJN ;
SCHNEERSON, R ;
ROBBINS, JB ;
SCHARFF, MD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (06) :1086-1093
[7]   SERUM THERAPY REVISITED - ANIMAL-MODELS OF INFECTION AND DEVELOPMENT OF PASSIVE ANTIBODY THERAPY [J].
CASADEVALL, A ;
SCHARFF, MD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1695-1702
[8]  
CASADEVALL A, CRYPTOCOCCUS NEOFORM
[9]   Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release [J].
Cleare, W ;
Casadevall, A .
MEDICAL MYCOLOGY, 1999, 37 (04) :235-243
[10]   The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays [J].
Cleare, W ;
Casadevall, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (02) :125-129